{"entity":{"id":"nct06558773","kind":"trial","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","aka":[],"tldr":"A phase 2 trial of regorafenib in colorectal cancer, run by Chinese PLA General Hospital, now recruiting.","summary":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. is a phase 2, randomised interventional study registered as NCT06558773 by Chinese PLA General Hospital, with a registry enrolment figure of 120 participants, started 2026-03-01 and due to reach its primary completion in 2027-03-01. Interventions recorded: Regorafenib+Immune checkpoint inhibitor; Eliglustat+Immune checkpoint inhibitor; Eliglustat+Immune checkpoint inhibitor +Regorafenib. Conditions listed: Colorectal Cancer. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: \"Histologically confirmed diagnosis of unresectable locally advanced, recurrent or metastatic colorectal cance have failed at least two lines of prior treatment\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06558773","url":"https://clinicaltrials.gov/study/NCT06558773"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06558773","phase":"2","setting":"GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor and/or Regorafenib for Patients With Advanced/Metastatic pMMR/MSS Colorectal Cancer:an Open-Label, Randomized,Phase II Study","sponsor":"Chinese PLA General Hospital","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06558773/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}